Moleculin Biotech (NASDAQ:MBRX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Moleculin Biotech (NASDAQ:MBRXGet Rating) issued its quarterly earnings data on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03), Fidelity Earnings reports.

Moleculin Biotech stock traded up $0.05 during mid-day trading on Friday, hitting $1.24. The company’s stock had a trading volume of 52,257 shares, compared to its average volume of 94,137. The company has a 50 day moving average of $1.63 and a 200-day moving average of $1.79. Moleculin Biotech has a one year low of $1.02 and a one year high of $3.99.

Institutional investors have recently made changes to their positions in the business. Morgan Stanley bought a new position in Moleculin Biotech in the 1st quarter valued at $39,000. Goldman Sachs Group Inc. purchased a new stake in shares of Moleculin Biotech in the 2nd quarter worth $94,000. Renaissance Technologies LLC purchased a new stake in shares of Moleculin Biotech in the 4th quarter worth $62,000. Citadel Advisors LLC lifted its holdings in shares of Moleculin Biotech by 174.9% in the 2nd quarter. Citadel Advisors LLC now owns 38,053 shares of the company’s stock worth $140,000 after buying an additional 24,210 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Moleculin Biotech in the 4th quarter worth $87,000. 10.57% of the stock is currently owned by institutional investors.

Separately, StockNews.com assumed coverage on Moleculin Biotech in a research report on Tuesday. They set a “sell” rating on the stock.

Moleculin Biotech Company Profile (Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Read More

Earnings History for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.